Like all big pharmas reinventing themselves post patent cliff, GlaxoSmithKline is staying busy. It just received FDA approval for two new melanoma drugs and snatched up a Swiss vaccine company for roughly $325 million.
In this video, health-care analyst David Williamson discusses what these two big pieces of news mean for Glaxo investors and also for its competitors.
Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.